Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion. -- Ignore unavailable to you. Want to Upgrade?

To: Aerobleu who wrote (59825)	8/22/2000 11:07:47 AM
From: lindao	Respond to of 150070

This part especially ... The company will use this proprietary database as a foundation for its first SNP/Haplotype association and linkage disequilibrium studies for Pharmacogenomics and breast cancer. In addition to providing a proprietary database resource platform not available through the public SNP database, it enables the company to conduct detailed and high-resolution studies well in advance of those organizations awaiting the completion of the public database. The Phenome(SM) database recently recorded its 2000th entry, and is scheduled to add its 5,000th entry later this year. To the companies knowledge, it is one of the first databases of its kind to focus on resolution within "important" genes rather than across the entire genome, and will offer the company a decided advantage in its high-throughput SNP/Haplotype scoring studies. The company intends to copyright the database, and patent its components discovered to be associated with clinical pathologies as "diagnomics" products. I can't help but just wonder about institutional interest in DNAP. Linda